Seelos Therapeutics, Inc. Cash Flow-to-Debt Ratio
Seelos Therapeutics, Inc. cash flow-to-debt ratio. Seelos Therapeutics, Inc. (SEELQ) has a Cash Flow-to-Debt Ratio of -0.03x as of June 2024, meaning its operating cash flow of $-972.00K could theoretically repay 0% of its total liabilities ($30.51 Million) in one year. Check Seelos Therapeutics, Inc. (SEELQ) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Seelos Therapeutics, Inc. (2020–2023)
Cash flow-to-debt ratio of Seelos Therapeutics, Inc. from 2020 to 2023. Historical debt coverage capacity for Seelos Therapeutics, Inc. across 4 annual periods. Also explore how fast is Seelos Therapeutics, Inc. growing its equity to track the company's year-over-year net asset growth rate.
Seelos Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2020–2023)
Seelos Therapeutics, Inc. cash flow-to-debt ratio by year from 2020 to 2023. Year-by-year debt coverage analysis for Seelos Therapeutics, Inc.. For the full cash flow conversion analysis, see how efficiently does Seelos Therapeutics, Inc. generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.61x | $-23.91 Million | $38.93 Million | ▲ +66.7% |
| 2022 | -1.85x | $-61.60 Million | $33.36 Million | ▲ +1.3% |
| 2021 | -1.87x | $-48.99 Million | $26.18 Million | ▼ -33.5% |
| 2020 | -1.40x | $-20.91 Million | $14.92 Million | — |